BALA CYNWYD, Pa. -- (Business Wire)

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of DUSA Pharmaceuticals, Inc. (“DUSA” or the “Company”) (Nasdaq: DUSA) relating to the proposed acquisition by Sun Pharmaceutical Industries Ltd. (“Sun”).

Under the terms of the transaction, DUSA shareholders will receive only $8.00 in cash for each share of DUSA stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of DUSA for not acting in the Company’s shareholders' best interests in connection with the sale process to Sun. The transaction may undervalue the Company and will not result in any substantial gain for many DUSA shareholders as DUSA stock traded at $7.00 on October 16, 2012. In addition, an analyst has set a $9.50 per share price target for DUSA.

If you own shares of DUSA stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com visiting http://brodsky-smith.com/501-dusa-dusa-pharmaceuticals-inc.html, by calling toll free 877-LEGAL-90.

Contacts:

Brodsky & Smith, LLC
Jason L. Brodsky, Esquire
Evan J. Smith, Esquire
877-LEGAL-90
investorrelations@brodsky-smith.com
http://brodsky-smith.com/501-dusa-dusa-pharmaceuticals-inc.html

Source: Brodsky & Smith, LLC